Introduction {#s1}
============

Stargardt disease (STGD1; Online Mendelian Inheritance in Man, 248200) is the most common inherited macular dystrophy with a prevalence of 1 in 8000 to 10,000.[@i2164-2591-8-2-1-b01][@i2164-2591-8-2-1-b02][@i2164-2591-8-2-1-b03][@i2164-2591-8-2-1-b04][@i2164-2591-8-2-1-b05][@i2164-2591-8-2-1-b06]--[@i2164-2591-8-2-1-b07] Onset is most commonly in childhood where patients present with bilateral central visual loss and characteristic macular atrophy with yellow--white flecks at the level of the retinal pigment epithelium (RPE) at the posterior pole.[@i2164-2591-8-2-1-b01],[@i2164-2591-8-2-1-b02],[@i2164-2591-8-2-1-b05],[@i2164-2591-8-2-1-b08],[@i2164-2591-8-2-1-b09] STGD1 has an autosomal-recessive mode of inheritance associated with disease-causing sequence variants in the ATP-binding cassette, subfamily A, member 4 (*ABCA4*) gene (Mendelian Inheritance in Man, 601691).[@i2164-2591-8-2-1-b01],[@i2164-2591-8-2-1-b10][@i2164-2591-8-2-1-b11][@i2164-2591-8-2-1-b12]--[@i2164-2591-8-2-1-b13] *ABCA4* encodes the retinal specific transmembrane protein,[@i2164-2591-8-2-1-b14],[@i2164-2591-8-2-1-b15] which is localized to the rim of rod and cone outer segment discs and involved in the active transport of retinoids from photoreceptors to RPE.[@i2164-2591-8-2-1-b14][@i2164-2591-8-2-1-b15]--[@i2164-2591-8-2-1-b16] ABCA4 dysfunction results in lipofuscin accumulation in the RPE[@i2164-2591-8-2-1-b14],[@i2164-2591-8-2-1-b17],[@i2164-2591-8-2-1-b18] and toxic levels of lipofuscin in the RPE are associated with photoreceptor degeneration and ultimately RPE loss.[@i2164-2591-8-2-1-b19][@i2164-2591-8-2-1-b20]--[@i2164-2591-8-2-1-b21]

A robust measurement of photoreceptor integrity is therefore crucial for monitoring disease progression and for the design of any treatment strategy. The ellipsoid zone (EZ) is a hyperreflective layer in the outer retina and has been associated with photoreceptor integrity and function. Spectral-domain optical coherence tomography (SD-OCT) enables in vivo high-resolution cross-sectional retinal images, allowing for quantitative assessments of the EZ, including manual identification of the transverse EZ loss and delineation of the area of EZ loss from an en face image. The EZ has been characterized in STGD1,[@i2164-2591-8-2-1-b22][@i2164-2591-8-2-1-b23]--[@i2164-2591-8-2-1-b24] yet only one study has tracked progression by the presence or absence of the EZ using en face OCT.[@i2164-2591-8-2-1-b25]

Despite increasing evidence that early-onset STGD1 belongs to the severe end of the spectrum of *ABCA4*-associated retinal phenotypes,[@i2164-2591-8-2-1-b04],[@i2164-2591-8-2-1-b07],[@i2164-2591-8-2-1-b26] no studies have assessed the EZ cross-sectionally or longitudinally in an exclusively pediatric population. Measuring photoreceptor layer integrity in children would be valuable in understanding the natural history of STGD1 in young patients and help determine whether children have better retinal potential for therapeutic intervention. Here, we evaluate the reliability of both the width of transverse loss of EZ and the area of EZ loss from en face SD-OCT analysis, as well as track disease progression to determine whether the EZ could serve as a robust anatomic outcome measure in children with molecularly confirmed STGD1.

Methods {#s2}
=======

This prospective observational study adhered to the tenets of the Declaration of Helsinki and was approved by the Moorfields Eye Hospital Ethics Committee. Informed consent and assent were obtained from parents and children, respectively, prior to entering the study.

Subjects {#s2a}
--------

A total of 46 children (mean age at baseline, 12.4 years; range, 6--18) with molecularly confirmed STGD1, from 39 pedigrees, including 19 males and 27 females, were included in this study. [Tables 1](#i2164-2591-8-2-1-t01){ref-type="table"} and [2](#i2164-2591-8-2-1-t03){ref-type="table"} summarizes the demographics and genetic findings for each subject.

###### 

Genetics

  Subject Number   Subject ID   Variant 1                       
  ---------------- ------------ ------------------------------- -------------------------------------
  P1               MM_0020      c.4918C\>T;c.4222T\>C           p.Arg1640Trp;p.Trp1408Arg
  P2               MM_0021      c.5882G\>A                      p.Gly1961Glu
  P3               MM_0058      c.5882G\>A                      p.Gly1961Glu
  P4               MM_0070      c.5882G\>A;c.3758C\>T           p.Gly1961Glu;p.Thr1253Met
  P5               MM_0090      c.3322C\>T                      p.Arg1108Cys
  P6               MM_0107      c.5161_5162delAC                p.Thr1721HisfsTer65
  P7               MM_0130      c.768G\>T                       p.Val256Val, Splice site alteration
  P8               MM_0138      *c.5898+2T\>C*                  *Splice site alteration*
  P9               MM_0146      c.5196+1137G\>A                 Deep intronic change
  P10              MM_0148      c.5461-10T\>C                   Splice site alteration
  P11              MM_0230      c.4139C\>T                      p.Pro1380Leu
  P12              MM_0227      *c.6391G\>A*                    *p.Glu2131Lys*
  P13              MM_0258      c.4793C\>A                      p.Ala1598Asp
  P14              MM_0286      c.4685T\>C                      p.Ile1562Thr
  P15              MM_0281      c.4469G\>A                      p.Cys1490Tyr
  P16              MM_0282      c.5461-10T\>C                   Splice-site alteration
  P17              MM_0284      c.1253T\>C                      p.Phe418Ser
  P18              MM_0312      c.3322C\>T                      p.Arg1108Cys
  P19              MM_0326      c.214G\>A                       p.Gly72Arg
  P20              MM_0356      c.1253T\>C                      p.Phe418Ser
  P21              MM_0291      c.1648G\>A                      p.Gly550Arg
  P22              MM_0026      c.5549T\>C                      p.Leu1850Pro
  P23              MM_0225      c.4469G\>A                      p.Cys1490Tyr
  P24              MM_0131      c.768G\>T                       p.Val256Val, splice-site alteration
  P25              MM_0360      c.214G\>A                       p.Gly72Arg
  P26              MM_0382      c.6445C\>T                      p.Arg2149Ter
  P27              MM_0399      c.1622T\>C; c.3113C\>T          p.Leu541Pro;p.Ala1038Val
  P28              MM_0421      *c.4571A\>G*                    *p.Asp1524Gly*
  P29              MM_0431      c.6320G\>A                      p.Arg2107His
  P30              MM_0432      c.4462T\>C                      p.Cys1488Arg
  P31              MM_0240      *c.29_30insT*                   *p.Leu10PhefsTer44*
  P32              MM_0113      c.6817-2A\>C                    Splice-site alteration
  P33              MM_0185      c.4918C\>T;c.4222T\>C           p.Arg1640Trp;p.Trp1408Arg
  P34              MM_0246      c.5461-10T\>C                   Splice-site alteration
  P35              MM_0260      *c.4539+2065C\>G*               *Deep intronic change*
  P36              MM_0314      c.5461-10T\>C                   Splice-site alteration
  P37              MM_0108      c.5161_5162delAC                p.Thr1721HisfsTer65
  P38              MM_0228      c.3113C\>T;c.1622T\>C           p.Ala1038Val;p.Leu541Pro
  P39              MM_0241      c.3064G\>A                      p.Glu1022Lys
  P40              MM_0426      c.6729+5_19delGTTGGCCCTGGGGCA   Splice-site alteration
  P41              MM_0433      c.6729+5_19delGTTGGCCCTGGGGCA   Splice-site alteration
  P42              MM_0351      c.1253T\>C                      p.Phe418Ser
  P43              MM_0310      c.885delC                       p.Asp295AspfsTer5
  P44              MM_0267      c.4469G\>A                      p.Cys1490Tyr
  P45              MM_0325      c.214G\>A                       p.Gly72Arg
  P46              MM_0335      c.6319C\>T                      p.Arg2107Cys

Reference: NM_000350.2.

Novel variants are shown in italics.

Pathogenicity of novel variants was assessed with the previously reported methods.[@i2164-2591-8-2-1-b11]

###### 

Extended

  Subject Number   Variant 2                       Variant 3                             
  ---------------- ------------------------------- ------------------------ ------------ -------------
  P1               *c.247_258insCAAA*              *p.Gln83ProfsTer17*                   
  P2               c.4793C\>A                      p.Ala1598Asp                          
  P3               c.454C\>T                       p.Arg152Ter                           
  P4               c.3364G\>A                      p.Glu1122Lys                          
  P5               c.3210_3211insGT                p.Ser1071CysfsTer14                   
  P6               c.2588G\>C                      p.Gly863Ala                           
  P7               c.634C\>T                       p.Arg212Cys                           
  P8               *c.286A\>T*                     *p.Asn96Tyr*                          
  P9               c.3364G\>A                      p.Glu1122Lys                          
  P10              c.3259G\>A                      p.Glu1087Lys                          
  P11              c.2588G\>C                      p.Gly863Ala                           
  P12              c.1957C\>T                      p.Arg653Cys              c.1411G\>A   p.Glu471Lys
  P13              c.2300T\>A                      p.Val767Asp                           
  P14              c.4469G\>A                      p.Cys1490Tyr             c.2588G\>C   p.Gly863Ala
  P15              c.3191-1G\>T                    Splice site alteration                
  P16              c.4363T\>C                      p.Cys1455Arg                          
  P17              c.1253T\>C                      p.Phe418Ser                           
  P18              c.454C\>T                       p.Arg152Ter                           
  P19              c.214G\>A                       p.Gly72Arg                            
  P20              c.3322C\>T                      p.Arg1108Cys                          
  P21              c.4918C\>T                      p.Arg1640Trp                          
  P22              c.4469G\>A                      p.Cys1490Tyr                          
  P23              c.6449G\>A                      p.Cys2150Tyr                          
  P24              c.634C\>T                       p.Arg212Cys                           
  P25              c.214G\>A                       p.Gly72Arg                            
  P26              c.5018+5G\>A                    Splice-site alteration                
  P27              c.5714+5G\>A                    Splice-site alteration                
  P28              *c.4571A\>G*                    *p.Asp1524Gly*                        
  P29              *c.2385C\>G*                    *p.Ser795Arg*                         
  P30              c.5882G\>A                      p.Gly1961Glu                          
  P31                                                                                    
  P32              c.1906C\>T                      p.Gln636Ter                           
  P33              *c.247_250insCAAA*              *p.Gln83ProfsTer17*                   
  P34              *c.4326C\>A*                    *p.Asn1442Lys*                        
  P35              c.6118C\>T                      p.Arg2040Ter                          
  P36              c.4139C\>T                      p.Pro1380Leu                          
  P37              c.2588G\>C                      p.Gly863Ala                           
  P38                                                                                    
  P39              c.3064G\>A                      p.Glu1022Lys                          
  P40              c.6729+5_19delGTTGGCCCTGGGGCA   Splice-site alteration                
  P41              c.6729+5_19delGTTGGCCCTGGGGCA   Splice-site alteration                
  P42              c.4773+1G\>T                    Splice-site alteration                
  P43              c.1804C\>T                      p.Arg602Trp                           
  P44              c.5318C\>A                      p.Ala1973Glu                          
  P45              c.214G\>A                       p.Gly72Arg                            
  P46              c.5461-10T\>C                   Splice site alteration                

###### 

Subject Demographics and Ellipsoid Zone Measurements

  Subject Number   Age at Baseline, y    Sex  Follow-Up Time, mo   Width of Ellipsoid Zone Loss, μm   Area of Ellipsoid Zone Loss, mm^2^                                           
  ---------------- -------------------- ----- -------------------- ---------------------------------- ------------------------------------ ------- ------- ------- ------- ------- -------
  P1               8                      F   52                   3615                               3524                                 4152    4090    6.7     7.24    10.92   11.34
  P2^a^            15                     M   51                   2118                               2466                                 3209    2976    3.66    3.55    4.67    4.52
  P3               16                     M   22                   1630                               1678                                 1623    1720    0.95    1.2     1.26    1.29
  P4               16                     F   23                   1637                               1472                                 1931    1789    1.81    1.41    2.11    2.14
  P5               14                     F   38                   3289                               2749                                 3694    3674    5.68    5.86    7.99    7.33
  P6               16                     F   44                   1235                               1175                                 1395    1360    0.71    0.85    0.97    0.96
  P7               8                      M   24                   984                                1071                                 1263    1222    0.45    0.49    1.14    0.95
  P8               8                      M   29                   3359                               2553                                 3834    3598    6.21    6.19    8.18    7.7
  P9               17                     F   30                   2901                               2517                                 3546    3775    3.87    4.06    8.7     9.41
  P10              15                     F   27                   3462                               3838                                 4172    3860    7.97    8.55    9.07    9.46
  P11              16                     F   23                   966                                998                                  1019    1063    0.51    0.54    0.51    0.58
  P12              14                     F   25                   991                                1472                                 1420    19811   0.47    1.27    1.78    2.02
  P13              15                     F   12                   3619                               2678                                 3919    3302    8.24    7.76    9.38    8.52
  P14              17                     M   12                   3413                               3576                                 3698    3772    5.33    5.49    6.07    6.47
  P15              9                      F   12                   3975                               3953                                 4504    4277    9.59    9.17    12.1    12.31
  P16              11                     F   25                   4337                               3416                                 4664    4740    10.61   9.49    12.85   12.07
  P17              12                     M   24                   3803                               3813                                 3681    3827    8.04    7.74    8.33    8.28
  P18              11                     F   18                   3611                               3448                                 4897    4752    9.29    9.55    10.9    12.61
  P19              8                      M   17                   4075                               3830                                 4159    4201    9.01    8.06    10.78   9.98
  P20              10                     M   12                   1323                               1215                                 1469    1465    0.76    0.76    1       0.96
  P21              13                     M   13                   1693                               1972                                 3550    2980    3.17    3.86    4.04    4.9
  P22              11                     F   40                   3623                               3725                                 4022    3969    9.61    8.78    12.11   10.67
  P23              8                      M   NA                   5009                               4809                                 NA^b^   NA^b^   17.41   18.12   NA^b^   NA^b^
  P24              10                     F   NA                   714                                787                                  NA^c^   NA^c^   0.24    0.21    NA^c^   NA^c^
  P25              8                      F   NA                   3811                               4451                                 NA^c^   NA^c^   13.11   13.29   NA^c^   NA^c^
  P26              11                     F   NA                   2829                               3200                                 NA^c^   NA^c^   4.35    4.93    NA^c^   NA^c^
  P27              17                     F   NA                   5311                               5767                                 NA^c^   NA^c^   15.06   15.89   NA^c^   NA^c^
  P28              14                     F   NA                   5590                               5408                                 NA^b^   NA^b^   14.98   16.19   NA^b^   NA^b^
  P29              17                     M   NA                   3909                               3729                                 NA^c^   NA^c^   9.5     10.21   NA^c^   NA^c^
  P30              17                     M   NA                   648                                776                                  NA^c^   NA^c^   0.29    0.28    NA^c^   NA^c^
  P31              10                     M   NA                   2540                               2520                                 NA^c^   NA^c^   4.27    4.26    NA^c^   NA^c^
  P32              17                     F   35                   3336                               3473                                 4721    5471    6.77    6.96    18.99   22.45
  P33              6                      F   32                   4235                               4536                                 4996    5277    9.86    10.14   17.89   NA^b^
  P34              12                     M   27                   5389                               4786                                 5509    6034    18.57   15.18   23.31   NA^b^
  P35              12                     F   27                   4973                               4646                                 NA^b^   5165    13.91   12.66   NA^b^   14.95
  P36              15                     F   17                   4478                               5074                                 5428    NA^b^   10.51   12.43   17.61   NA^b^
  P37              12                     F   44                   NA^b^                              964                                  1183    1184    NA^b^   0.58    0.58    0.69
  P38              14                     F   29                   4972                               NA^b^                                5573    5336    15.62   NA^b^   20.8    19.07
  P39              18                     F   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P40              8                      M   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P41              12                     M   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P42              10                     M   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P43              8                      M   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P44              12                     M   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P45              9                      F   NA                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^
  P46              14                     F   15                   NA^b^                              NA^b^                                NA^b^   NA^b^   NA^b^   NA^b^   NA^b^   NA^b^

F, female; M, male; NA, not available.

Foveal Sparing.

Ellipsoid Zone loss extending beyond the border of the scans.

No follow-up visits available.

SD-OCT Image Acquisition {#s2b}
------------------------

All subjects underwent SD-OCT imaging using the Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany). A transfoveal horizontal line scan was acquired for the measurement of the extent of the transverse loss of the EZ. The protocol also included two horizontal volume scans centered at the fovea covering a 20° × 20° area to enable an en face analysis for the measurement of the area of EZ loss. The first volume scan comprised 49 horizontal B-scans with 124-μm interscan spacing, and the second comprised of 193 horizontal B-scans with 31-μm interscan spacing. The SD-OCT scans were automatically registered to a near-infrared reflectance (NIR-R) fundus image, which was acquired simultaneously. All scans were obtained using the automatic retinal tracking (ART) mode and automatic registration was used for all follow-up scans.

SD-OCT Image Analysis {#s2c}
---------------------

Images for each subject were analyzed using the Heidelberg Eye Explorer software (version 1.9.10.0; Heidelberg Engineering) and were displayed in the 1:1-μm setting. The acquired transfoveal horizontal line scan was used to measure the extent of the transverse loss of the EZ. The nasal and temporal location of the EZ loss, identified as the point where the hyperreflective EZ was no longer discernible/continuous, was manually demarcated with the arrow tool. The caliper tool was then used to delineate the width of the transverse loss of the EZ, which was automatically calculated by the software. In all patients, with the exception of P2, no residual EZ structure was visible between the nasal and temporal borders. For consistency we decided to measure the EZW in the same way in P2 with 'foveal sparing\', as undertaken in the rest of the cohort.

The acquired macula volume scans and associated NIR-R fundus image were used for en face analysis to measure the extent of the area of EZ loss. En face analysis was done manually by assessing each individual B-scan. All B-scans had a quality index greater than 25 dB. The nasal and temporal location of the EZ loss for each consecutive B-scan was marked and the corresponding locations were annotated on the NIR-R fundus image. Once all the nasal and temporal borders were marked, the region finder tool was used to join the points delineating the area of EZ loss on the NIR-R fundus image and the area value was automatically calculated by the software. The denser scan, when available, was preferentially used for analysis. In a few patients the less dense scans were used because of better image quality (more reliable identification of EZ borders), because for the less dense scans it was easier to keep the ART at a higher value. In addition, having multiple scans at both baseline and follow-up made it easier to identify the exact same location for measuring EZW and track rate of progression over time, especially in cases where the single line scans were not over the same exact location at follow-up visit.

Baseline and follow-up line and volume scans from both eyes were analyzed twice in a masked fashion by two graders (PT and MG) to determine the reliability of both EZ measurements. Graders were masked to their previous measurements, as well as the measurement of the other grader. Measurements were repeated at least 1 week apart. Both graders have practiced the method in 10 scans (data not used for the study). The results were comparable between graders and so it was decided to apply the method to the study. In terms of expertise, both graders are postgraduate students with 3 (PT) and 1.5 (MG) years of experience in clinical research in inherited retinal diseases (IRDs) and retinal imaging.

All measurements, both at baseline and follow-up, given their transverse nature, were corrected using the ratio between the assumed axial length of the OCT system (24 mm) and the actual axial length measurement for that eye (Zeiss IOL Master; Carl Zeiss Meditec, Dublin, CA).

Statistical Methods {#s2d}
-------------------

The statistical analysis was carried out for transverse EZ loss measurements and area of EZ loss measurements using SPSS Statistics (Chicago). Significance for all statistical tests was set at *P* \< 0.05. The Shapiro-Wilk test was used to test for normality for all variables.

A multilevel mixed-effects model was fitted with random grader and subject effects and intra- and intergrader reliability were assessed by the intraclass correlation coefficient (ICC). The annual rate of transverse EZ loss and area of EZ loss was calculated for each eye.

The interocular symmetry was assessed with paired *t*-test for both, area and width measurements, at baseline and follow-up as well as annual rates of EZ loss. Interocular correlation between eyes in the baseline measurements, follow-up measurements, and annual rate of transverse EZ loss and annual rate of area of EZ loss were assessed with Pearson\'s correlation coefficient.

The difference between eyes in the baseline measurement, follow-up measurement, and the annual rate of progression was assessed using the paired-samples *t*-test. The correlations between eyes were assessed with the Pearson\'s correlation coefficient. Subsequently, the strength of the correlations between the baseline measurement and annual rate of progression, baseline measurement, and age at baseline as well as the age at baseline and annual rate of progression were assessed with the Pearson\'s correlation coefficient. Strong, moderate, and weak correlation was set as *r* \> 0.7, 0.7 \> *r* \> 0.5, and *r* \< 0.5, respectively.

Results {#s3}
=======

Thirty-eight subjects (P1--P38) underwent baseline testing on both eyes and contributed to the reliability analysis at baseline. The data from seven subjects (P39--P45) could not be analyzed as the baseline images showed the loss to extend beyond the SD-OCT scan limits. In contrast, subject P46 who was asymptomatic when recruited and was followed-up for 15 months, showed a healthy EZ at baseline and follow-up bilaterally, and thereby excluded from the analysis. Twenty-two of these subjects (P1--P22) also underwent follow-up testing on both eyes and contributed to the reliability analysis at follow-up to assess reliability at a later cross-section in time. Nine subjects either did not have follow-up visits (*n* = 7) or their EZ loss extended beyond the area imaged with OCT (*n* = 2), and thereby were excluded from longitudinal analysis. In patients P32 to P38 ([Table 2](#i2164-2591-8-2-1-t03){ref-type="table"}), missing measurements are due to the EZ loss extending beyond the scan borders; with the exception of P37, which was due to poor compliance at baseline image acquisition. Some patients have only an EZW, because technically it was easier to center the lesion for a single line scan, and they thereby lack an EZ area because the whole area of the lesion was not imaged in the volume scans (e.g., P33 and P34). All measured variables were normally distributed. [Table 2](#i2164-2591-8-2-1-t03){ref-type="table"} summarizes all measurements.

Intragrader and Intergrader Reliability {#s3a}
---------------------------------------

Data from the right eye of all subjects were used for this analysis, after proving disease symmetry and in order to avoid any clustering effect. At baseline, the mean absolute difference in the transverse EZ loss on repeat measurement for grader 1 (PT) and grader 2 (MG) was 223.2 ± 178.5 and 176.4 ± 196.6 μm, respectively, and between graders after averaging their two sets of measurements was 161.3 ± 137.6 μm. The intragrader ICC at baseline for both graders and the intergrader ICC was 0.99. At follow-up, the mean absolute difference in the transverse EZ loss on repeat measurement for graders 1 and 2 was 279.5 ± 362.1 and 255.3 ± 331.6 μm, respectively, and between graders, after averaging their two sets of measurements, was 89.6 ± 79.1 μm. The intragrader ICC at follow-up for both graders was 0.98, and intergrader ICC was 0.99.

At baseline, the mean absolute difference in the area of EZ loss on repeat measurement for graders 1 and 2 was 0.42 ± 0.38 and 0.41 ± 0.39 mm^2^, respectively, and between graders, after averaging their two sets of measurements, was 0.28 ± 0.33 mm^2^. The intragrader ICC at baseline for both graders and the intergrader ICC was 0.99. At follow-up, the mean absolute difference in the area of EZ loss on repeat measurement for graders 1 and 2 was 0.43 ± 0.38 and 0.55 ± 0.76 mm^2^, respectively, and between graders, after averaging their two sets of measurements, was 0.23 ± 0.24 mm^2^. The intragrader and the intergrader ICC at follow-up for both graders was 0.99.

Interocular Symmetry {#s3b}
--------------------

Data from the 22 subjects (P1--P22) with baseline and follow-up testing on both eyes were analyzed further to assess interocular symmetry.

The mean absolute difference after averaging all four baseline measurements (2 from each observer) of the transverse EZ loss between eyes was 289.0 ± 291.3 μm; and in the follow-up measurement was 176.4 ± 168.5 μm. The mean difference in the annual rate of transverse EZ loss between eyes was 158.9 ± 194.6 μm/y. There was no statistically significant difference between eyes in the baseline measurement (*P* = 0.092), follow-up measurement (*P* = 0.209), and annual rate of EZ loss width (*P* = 0.726). There was a strong positive correlation between eyes in the baseline measurement (*r* = 0.95), follow-up measurement (*r* = 0.98), and annual rate of transverse EZ loss (*r* = 0.75).

The mean absolute difference in the baseline measurements of the area of EZ loss between eyes was 0.39 ± 0.33 mm^2^ and in the follow-up measurement was 0.48 ± 0.46 mm^2^. The mean difference in the annual rate of area of EZ loss between eyes was 0.21 ± 0.22 mm^2^/y. There was no statistically significant difference between eyes in the baseline measurement (*P* = 0.75), follow-up measurement (*P* = 0.923), and annual rate of area of EZ loss (*P* = 0.424). There was a strong positive correlation between eyes in the baseline measurement (*r* = 0.99), follow-up measurement (*r* = 0.99), and annual rate of area of EZ loss (*r* = 0.94) ([Fig. 1](#i2164-2591-8-2-1-f01){ref-type="fig"}).

![Representation of interocular symmetry of EZ loss measurements of a 20 years old female (P6) with STGD1 at the 4 years follow-up visit. The areas of EZ loss are delineated with blue lines on the NIR-R images and the area imaged in the OCT B-scan below is represented with blue arrows. The blue arrows on the OCT images mark the boundaries of the EZ loss. The disease shows high interocular symmetry in this individual. All images on the first two rows are at the same scale. The delineated areas with the white rectangle are magnified (×3) in the third row.](i2164-2591-8-2-1-f01){#i2164-2591-8-2-1-f01}

Rate of Progression {#s3c}
-------------------

A total of 29 subjects (P1--P22, P32--P38; mean age at baseline, 12.7 years; range, 6--17) with both baseline and follow-up testing on at least one eye were included to determine the annual rate of progression. In subjects with testing on both eyes, one eye was chosen at random, given the symmetry between eyes, for the examined parameters. The mean follow-up period for this subgroup was 27 months (range, 12--52 months). [Figure 2](#i2164-2591-8-2-1-f02){ref-type="fig"} shows representative examples of the variability in progression.

![Disease progression in two STGD1 patients. The areas of EZ loss are delineated with blue lines on the NIR-R images and the section imaged in the OCT B-scan below is represented with green lines. The blue arrows on the OCT images mark the boundaries of the EZ loss. Patient (A) is a 16-years-old female (P11) with 24 months of follow-up. The disease was relatively stable for that patient with an annual rate of EZ area loss of 0.02 mm^2^ and of EZ width expansion of 33 μm/y. Patient (B) is a 14-year-old female (P5) with rapid disease progression over 38 months, with an annual rate of EZ area loss of 0.73 mm^2^ and of EZ width loss of 128 μm. The delineated areas with the white rectangles are magnified (×3) in the third row of panels (A) and (B).](i2164-2591-8-2-1-f02){#i2164-2591-8-2-1-f02}

The mean annual rate of transverse EZ loss was 279.5 ± 259.9 μm/y. The mean baseline measurement of the transverse EZ loss was 2939.9 ± 1294.0 μm. There was a weak positive correlation (*r* = 0.15) between the baseline measurement and the annual rate of transverse EZ loss, and a weak negative correlation (*r* = −0.21) between the baseline measurement and age at baseline. There was no correlation between the age at baseline and annual rate of transverse EZ loss (*r* = −0.01).

The mean annual rate of area of EZ loss was 1.20 ± 1.29 mm^2^/y. The mean baseline measurement of area of EZ loss was 6.43 ± 4.67 mm^2^. There was a strong moderate positive correlation (*r* = 0.55) between the baseline measurement and the annual rate of area of EZ loss, and a weak negative correlation (*r* = −0.22) between the baseline measurement and age at baseline. There was no correlation between the age at baseline and annual rate of area of EZ loss (*r* = −0.03) ([Fig. 2](#i2164-2591-8-2-1-f02){ref-type="fig"}).

The mean annual rates of transverse EZ loss and area of EZ loss were 10.2 ± 9.9%/y and 19.4 ± 16.3 %/y respectively, which were significantly different (*P* = 0.004). [Figure 3](#i2164-2591-8-2-1-f03){ref-type="fig"} illustrates the variability in the percentage annual rate of loss.

![Stacked scatterplot showing the variability of the percentage annual rate of change in transverse EZ loss and area of EZ loss. Values represent mean ± SD.](i2164-2591-8-2-1-f03){#i2164-2591-8-2-1-f03}

Discussion {#s4}
==========

This is the first prospective study on the characterization of the EZ in a large cohort of molecularly confirmed children with STGD1. The high intra- and intergrader ICCs of both the transverse EZ loss and area of EZ loss measurements, as well as the ability to detect change over time, suggests the EZ could serve as a robust anatomic outcome measure in children.

There are no studies in children with STGD1 on the quantification of EZ loss both cross-sectionally, and longitudinally to determine rates of progression. One study that characterized the baseline transverse EZ loss in STGD1 subjects (mean age 34.4 years) showed the mean measurement was 3911 ± 1423 μm.[@i2164-2591-8-2-1-b27] In our study, although the mean age of the cohort was notably younger (mean age 12.4 years), the mean baseline measurement of the transverse EZ loss was comparable (2939.9 ± 1294.0 μm). However, no studies have previously assessed rate of progression of the transverse EZ loss over time in STGD1.

Only one study has assessed the area of EZ loss longitudinally in STGD1 subjects (mean age 33.0 years) and demonstrated a gradual expansion in the area of EZ loss of 0.31 mm^2^/y, with the mean (± standard deviation) initial area of EZ loss being 4.18 ± 1.91 mm^2^.[@i2164-2591-8-2-1-b25] In contrast, our study identified a higher mean baseline measurement (6.43 ± 4.67 mm^2^), and notably the mean annual rate of area of EZ loss was more than 3 times faster (1.20 ± 1.29 mm^2^/year). This is likely to be due to our cohort having earlier-onset disease associated with more rapid progression than adult cohorts.[@i2164-2591-8-2-1-b04] This is also supported by the relatively high proportion (52%) of subjects harboring severe disease-causing variants in our cohort that would be expected to affect splicing, or to introduce a premature truncating codon in the protein if translated.

All measurements were higher than the inherent variability in measurements taken from Spectralis images (lateral optical resolution = 14 μm). However, the data from seven subjects (P39--P45) were excluded as the baseline images showed the loss to extend beyond the limits of the SD-OCT scan. Six of these subjects were aged 12 or younger at baseline. This indicates that the phenotype can be variable, with highly progressive disease from early childhood, highlighting the importance of analyzing children and adults independently, and there is a group of children who have very rapidly progressive disease who would be ideal for clinical trials both in terms of rapid readouts and also potentially deriving the most benefit.

The inter- and intragrader reliability of EZ area and transverse EZ measurements in this study were consistently excellent. The annual rate of transverse EZ loss was 10.2 ± 9.9%/y and the annual rate of area of EZ loss was significantly higher at 19.4 ± 16.3%/y. Although both measurements are assessing the EZ, measuring transverse EZ loss is considerably quicker as only a single image is analyzed. In contrast, EZ area measurements require several B-scans to be analyzed and therefore the resulting value is based on more than a single measurement. Assessing the area of EZ loss is more time consuming yet evidently may be twice as sensitive in measuring progression in children compared with measuring transverse EZ loss. Furthermore, the area of EZ loss may provide greater statistical power to detect significant differences in a given sample and may also be a more robust outcome measure in observational studies or therapeutic trials. There are other potential endpoints derived from SD-OCT measurements under investigation in STGD1, including total macular volume.[@i2164-2591-8-2-1-b28]

The annual rate of area of EZ loss showed a stronger correlation with the baseline measurement compared with the annual rate of transverse EZ loss; suggesting the area of EZ may be more valuable in assessing prognosis---with baseline EZ area better predictive of progression than baseline EZ width. However, both baseline measurements showed a weak negative correlation with age at baseline. These findings are in keeping with younger children presenting with larger width and area of EZ loss at baseline, leading to a higher annual rate of EZ loss. In other words, subjects with earlier onset present with a severe and rapidly progressive phenotype at the photoreceptor microstructural level, in keeping with other clinical parameters.[@i2164-2591-8-2-1-b04] Given this greater rate of progression in children, they represent good candidates for therapeutic intervention, thereby highlighting the need to initiate structural assessments in cohorts of young children.

Interocular symmetry in terms of baseline measurements, follow-up measurements, and annual rate of loss was observed. Although both EZ measurements showed a strong correlation and no significant difference between eyes in the baseline measurement, follow-up measurement, and annual rate of loss, the EZ area measurements consistently showed a higher correlation between eyes. This is valuable for future treatment strategies both for stratification, because both eyes appear to have comparable potential as well as for the use of the nontreated eye as 'control\'.

Image quality affected subsequent analysis for both transverse and area EZ measurements. Poor image quality makes EZ borders on line scans less distinct. In addition, because scans for 15% of the subjects were excluded from analysis as the initial loss extended beyond the scan area, it is important to be aware of this potential limitation of the testing device for children with a severe phenotype/high rate of progression and those at advanced stages of disease. Widefield SD-OCT and swept-source OCT imaging may help address this limitation.

In conclusion, this is the first prospective study on the quantification of EZ loss in children with molecularly confirmed STGD1 and highlights the utility of SD-OCT in measuring EZ loss in young subjects. In this cohort, measuring the area of EZ loss was more sensitive compared with transverse EZ loss measurements, and will be valuable both for monitoring disease progression and clinical trials requiring a robust structural outcome measure.
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